Do analysts recommend BJDX or TNON?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tenon Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor BJDX or TNON?

In the previous week, Bluejay Diagnostics had 7 more articles in the media than Tenon Medical. MarketBeat recorded 9 mentions for Bluejay Diagnostics and 2 mentions for Tenon Medical. Tenon Medical's average media sentiment score of 0.94 beat Bluejay Diagnostics' score of 0.39 indicating that Tenon Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bluejay Diagnostics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tenon Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NVNO or BJDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, NVNO or BJDX?

enVVeno Medical is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enVVeno Medical N/A N/A -$19.47M -$25.54 N/A Bluejay Diagnostics N/A N/A -$6.85M -$11.63 N/A

Is NVNO or BJDX more profitable?

enVVeno Medical's return on equity of -66.39% beat Bluejay Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets enVVeno Medical N/A -66.39% -60.42% Bluejay Diagnostics N/A -144.27% -115.00%

Does the media refer more to NVNO or BJDX?

In the previous week, Bluejay Diagnostics had 7 more articles in the media than enVVeno Medical. MarketBeat recorded 9 mentions for Bluejay Diagnostics and 2 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 0.97 beat Bluejay Diagnostics' score of 0.39 indicating that enVVeno Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enVVeno Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bluejay Diagnostics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate RBOT or BJDX?

Vicarious Surgical presently has a consensus price target of $7.00, indicating a potential upside of 1,246.15%. Given Vicarious Surgical's stronger consensus rating and higher probable upside, equities analysts plainly believe Vicarious Surgical is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, RBOT or BJDX?

Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vicarious Surgical N/A N/A -$63.22M -$6.69 N/A Bluejay Diagnostics N/A N/A -$6.85M -$11.63 N/A

Is RBOT or BJDX more profitable?

Bluejay Diagnostics' return on equity of -144.27% beat Vicarious Surgical's return on equity. Company Net Margins Return on Equity Return on Assets Vicarious Surgical N/A -184.13% -112.50% Bluejay Diagnostics N/A -144.27% -115.00%

Does the media favor RBOT or BJDX?

In the previous week, Bluejay Diagnostics had 7 more articles in the media than Vicarious Surgical. MarketBeat recorded 9 mentions for Bluejay Diagnostics and 2 mentions for Vicarious Surgical. Bluejay Diagnostics' average media sentiment score of 0.39 beat Vicarious Surgical's score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vicarious Surgical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bluejay Diagnostics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NDRA or BJDX?

ENDRA Life Sciences currently has a consensus target price of $25.00, indicating a potential upside of 465.61%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe ENDRA Life Sciences is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, NDRA or BJDX?

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ENDRA Life Sciences N/A N/A -$7.03M -$8.15 N/A Bluejay Diagnostics N/A N/A -$6.85M -$11.63 N/A

Is NDRA or BJDX more profitable?

Bluejay Diagnostics' return on equity of -144.27% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets ENDRA Life Sciences N/A -433.64% -204.58% Bluejay Diagnostics N/A -144.27% -115.00%

Do analysts recommend LUCY or BJDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innovative Eyewear 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to LUCY or BJDX?

In the previous week, Bluejay Diagnostics had 5 more articles in the media than Innovative Eyewear. MarketBeat recorded 9 mentions for Bluejay Diagnostics and 4 mentions for Innovative Eyewear. Bluejay Diagnostics' average media sentiment score of 0.39 beat Innovative Eyewear's score of 0.23 indicating that Bluejay Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innovative Eyewear 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bluejay Diagnostics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Bluejay Diagnostics (BJDX) Competitors

$4.50 -0.73 (-13.96%)

Closing price 04:00 PM Eastern

Extended Trading

$4.59 +0.09 (+2.02%)

As of 07:57 PM Eastern

Compare

BJDX vs. TNON, NVNO, RBOT, NDRA, and LUCY

Should you buy Bluejay Diagnostics stock or one of its competitors? MarketBeat compares Bluejay Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bluejay Diagnostics include Tenon Medical (TNON), enVVeno Medical (NVNO), Vicarious Surgical (RBOT), ENDRA Life Sciences (NDRA), and Innovative Eyewear (LUCY). These companies are all part of the "medical equipment" industry.

How does Bluejay Diagnostics compare to Tenon Medical?

Bluejay Diagnostics (NASDAQ:BJDX) and Tenon Medical (NASDAQ:TNON) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Bluejay Diagnostics has a net margin of 0.00% compared to Tenon Medical's net margin of -270.09%. Bluejay Diagnostics' return on equity of -144.27% beat Tenon Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-144.27%	-115.00%
Tenon Medical	-270.09%	-907.60%	-110.17%

Bluejay Diagnostics has higher earnings, but lower revenue than Tenon Medical. Tenon Medical is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A
Tenon Medical	$3.94M	1.81	-$12.56M	-$1.29	N/A

Bluejay Diagnostics has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Tenon Medical has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tenon Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Bluejay Diagnostics had 7 more articles in the media than Tenon Medical. MarketBeat recorded 9 mentions for Bluejay Diagnostics and 2 mentions for Tenon Medical. Tenon Medical's average media sentiment score of 0.94 beat Bluejay Diagnostics' score of 0.39 indicating that Tenon Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bluejay Diagnostics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenon Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 22.7% of Tenon Medical shares are held by institutional investors. 0.1% of Bluejay Diagnostics shares are held by company insiders. Comparatively, 0.3% of Tenon Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Tenon Medical beats Bluejay Diagnostics on 9 of the 14 factors compared between the two stocks.

How does Bluejay Diagnostics compare to enVVeno Medical?

enVVeno Medical (NASDAQ:NVNO) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

enVVeno Medical has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

enVVeno Medical's return on equity of -66.39% beat Bluejay Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-66.39%	-60.42%
Bluejay Diagnostics	N/A	-144.27%	-115.00%

enVVeno Medical is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47M	-$25.54	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A

34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 15.0% of enVVeno Medical shares are owned by insiders. Comparatively, 0.1% of Bluejay Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Bluejay Diagnostics had 7 more articles in the media than enVVeno Medical. MarketBeat recorded 9 mentions for Bluejay Diagnostics and 2 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 0.97 beat Bluejay Diagnostics' score of 0.39 indicating that enVVeno Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enVVeno Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bluejay Diagnostics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

enVVeno Medical beats Bluejay Diagnostics on 7 of the 11 factors compared between the two stocks.

How does Bluejay Diagnostics compare to Vicarious Surgical?

Vicarious Surgical (NYSE:RBOT) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 9.5% of Vicarious Surgical shares are owned by company insiders. Comparatively, 0.1% of Bluejay Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vicarious Surgical has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

Vicarious Surgical presently has a consensus price target of $7.00, indicating a potential upside of 1,246.15%. Given Vicarious Surgical's stronger consensus rating and higher probable upside, equities analysts plainly believe Vicarious Surgical is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Bluejay Diagnostics had 7 more articles in the media than Vicarious Surgical. MarketBeat recorded 9 mentions for Bluejay Diagnostics and 2 mentions for Vicarious Surgical. Bluejay Diagnostics' average media sentiment score of 0.39 beat Vicarious Surgical's score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vicarious Surgical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bluejay Diagnostics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A

Bluejay Diagnostics' return on equity of -144.27% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
Bluejay Diagnostics	N/A	-144.27%	-115.00%

Summary

Vicarious Surgical beats Bluejay Diagnostics on 8 of the 12 factors compared between the two stocks.

How does Bluejay Diagnostics compare to ENDRA Life Sciences?

ENDRA Life Sciences (NASDAQ:NDRA) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A

Bluejay Diagnostics' return on equity of -144.27% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-433.64%	-204.58%
Bluejay Diagnostics	N/A	-144.27%	-115.00%

ENDRA Life Sciences currently has a consensus target price of $25.00, indicating a potential upside of 465.61%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe ENDRA Life Sciences is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by insiders. Comparatively, 0.1% of Bluejay Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

ENDRA Life Sciences has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

In the previous week, ENDRA Life Sciences had 2 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 11 mentions for ENDRA Life Sciences and 9 mentions for Bluejay Diagnostics. ENDRA Life Sciences' average media sentiment score of 1.08 beat Bluejay Diagnostics' score of 0.39 indicating that ENDRA Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
ENDRA Life Sciences	Positive
Bluejay Diagnostics	Neutral

Summary

ENDRA Life Sciences beats Bluejay Diagnostics on 7 of the 13 factors compared between the two stocks.

How does Bluejay Diagnostics compare to Innovative Eyewear?

Innovative Eyewear (NASDAQ:LUCY) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

1.0% of Innovative Eyewear shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 1.7% of Innovative Eyewear shares are held by insiders. Comparatively, 0.1% of Bluejay Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Bluejay Diagnostics had 5 more articles in the media than Innovative Eyewear. MarketBeat recorded 9 mentions for Bluejay Diagnostics and 4 mentions for Innovative Eyewear. Bluejay Diagnostics' average media sentiment score of 0.39 beat Innovative Eyewear's score of 0.23 indicating that Bluejay Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innovative Eyewear	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bluejay Diagnostics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innovative Eyewear	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Innovative Eyewear has a beta of 2.66, indicating that its share price is 166% more volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

Bluejay Diagnostics has lower revenue, but higher earnings than Innovative Eyewear. Innovative Eyewear is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innovative Eyewear	$2.66M	2.17	-$7.59M	-$1.69	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A

Bluejay Diagnostics has a net margin of 0.00% compared to Innovative Eyewear's net margin of -272.42%. Innovative Eyewear's return on equity of -83.37% beat Bluejay Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innovative Eyewear	-272.42%	-83.37%	-76.02%
Bluejay Diagnostics	N/A	-144.27%	-115.00%

Summary

Innovative Eyewear beats Bluejay Diagnostics on 7 of the 13 factors compared between the two stocks.

Get Bluejay Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BJDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BJDX vs. The Competition

Export

Metric	Bluejay Diagnostics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.41M	$7.22B	$6.64B	$12.06B
Dividend Yield	N/A	1.20%	2.67%	5.55%
P/E Ratio	-0.39	39.75	20.93	22.06
Price / Sales	N/A	74.36	508.64	105.22
Price / Cash	N/A	24.77	42.36	56.09
Price / Book	0.53	6.99	10.47	6.72
Net Income	-$6.85M	$159.22M	$3.56B	$337.35M
7 Day Performance	3.69%	-1.54%	-1.11%	-2.54%
1 Month Performance	154.96%	2.94%	1.28%	1.42%
1 Year Performance	-43.47%	-2.51%	21.20%	24.71%

Bluejay Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BJDX Bluejay Diagnostics	1.4576 of 5 stars	$4.50 -14.0%	N/A	-41.9%	$5.41M	N/A	N/A	9	Short Interest Increase Gap Up
TNON Tenon Medical	1.5272 of 5 stars	$0.69 +0.1%	N/A	-40.0%	$8.02M	$3.94M	N/A	8
NVNO enVVeno Medical	1.192 of 5 stars	$11.13 -1.1%	N/A	-92.0%	$7.44M	N/A	N/A	30
RBOT Vicarious Surgical	1.6649 of 5 stars	$0.94 -1.9%	$7.00 +642.9%	-92.8%	$6.71M	N/A	N/A	210
NDRA ENDRA Life Sciences	3.4095 of 5 stars	$5.12 -1.6%	$30.00 +486.5%	+27.1%	$6.51M	N/A	N/A	20	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BJDX) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bluejay Diagnostics (BJDX) Competitors

BJDX vs. TNON, NVNO, RBOT, NDRA, and LUCY

How does Bluejay Diagnostics compare to Tenon Medical?

Summary

How does Bluejay Diagnostics compare to enVVeno Medical?

Summary

How does Bluejay Diagnostics compare to Vicarious Surgical?

Summary

How does Bluejay Diagnostics compare to ENDRA Life Sciences?

Summary

How does Bluejay Diagnostics compare to Innovative Eyewear?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BJDX vs. The Competition

Bluejay Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bluejay Diagnostics (BJDX) Competitors

BJDX vs. TNON, NVNO, RBOT, NDRA, and LUCY

How does Bluejay Diagnostics compare to Tenon Medical?

Is BJDX or TNON more profitable?

Which has higher valuation and earnings, BJDX or TNON?

Which has more risk and volatility, BJDX or TNON?

Do analysts recommend BJDX or TNON?

Does the media favor BJDX or TNON?

Do institutionals and insiders hold more shares of BJDX or TNON?

Summary

How does Bluejay Diagnostics compare to enVVeno Medical?

Do analysts rate NVNO or BJDX?

Which has more volatility and risk, NVNO or BJDX?

Is NVNO or BJDX more profitable?

Which has preferable valuation & earnings, NVNO or BJDX?

Do institutionals and insiders believe in NVNO or BJDX?

Does the media refer more to NVNO or BJDX?

Summary

How does Bluejay Diagnostics compare to Vicarious Surgical?

Do insiders & institutionals have more ownership in RBOT or BJDX?

Which has more risk and volatility, RBOT or BJDX?

Do analysts rate RBOT or BJDX?

Does the media favor RBOT or BJDX?

Which has preferable earnings & valuation, RBOT or BJDX?

Is RBOT or BJDX more profitable?

Summary

How does Bluejay Diagnostics compare to ENDRA Life Sciences?

Which has stronger valuation & earnings, NDRA or BJDX?

Is NDRA or BJDX more profitable?

Do analysts recommend NDRA or BJDX?

Do institutionals and insiders have more ownership in NDRA or BJDX?

Which has more volatility and risk, NDRA or BJDX?

Does the media refer more to NDRA or BJDX?

Summary

How does Bluejay Diagnostics compare to Innovative Eyewear?

Do insiders & institutionals believe in LUCY or BJDX?

Does the media refer more to LUCY or BJDX?

Do analysts recommend LUCY or BJDX?

Which has more volatility & risk, LUCY or BJDX?

Which has better valuation & earnings, LUCY or BJDX?

Is LUCY or BJDX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BJDX vs. The Competition

Bluejay Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools